US 12,064,476 B2
Zika virus immunogenic compositions
Lanying Du, Rego Park, NY (US); Wanbo Tai, Elmhurst, NY (US); and Fang Li, St. Paul, MN (US)
Assigned to New York Blood Center, Inc., New York, NY (US); and Regents of the University of Minnesota, Minneapolis, MN (US)
Appl. No. 17/287,938
Filed by New York Blood Center, Inc., New York, NY (US); and Regents of the University of Minnesota, Minneapolis, MN (US)
PCT Filed Oct. 25, 2019, PCT No. PCT/US2019/058210
§ 371(c)(1), (2) Date Apr. 22, 2021,
PCT Pub. No. WO2020/087038, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/751,470, filed on Oct. 26, 2018.
Prior Publication US 2021/0308250 A1, Oct. 7, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/55 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24171 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for preventing and/or treating a Zika viral infection in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of an isolated polypeptide comprising an altered structural envelope (E) protein domain III (EDIII);
wherein the isolated polypeptide comprises any of SEQ ID NOs 4-6 or 8-22, or a combination thereof; and
wherein the alteration reduces or prevents the immunogenicity of one or more interfering epitopes of the EDIII.